Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins

Abstract Background Considering the increasing use of polymyxins to treat infections due to multidrug resistant Gram-negative in many countries, it is important to evaluate different susceptibility testing methods to this class of antibiotic. Methods Susceptibility of 109 carbapenem-resistant P. aeruginosa to polymyxins was tested comparing broth microdilution (reference method), disc diffusion, and Etest using the new interpretative breakpoints of Clinical and Laboratory Standards Institute. Results Twenty-nine percent of isolates belonged to endemic clone and thus, these strains were excluded of analysis. Among 78 strains evaluated, only one isolate was resistant to polymyxin B by the reference method (MIC: 8.0 μg/mL). Very major and major error rates of 1.2% and 11.5% were detected comparing polymyxin B disc diffusion with the broth microdilution (reference method). Agreement within 1 twofold dilution between Etest and the broth microdilution were 33% for polymyxin B and 79.5% for colistin. One major error and 48.7% minor errors were found comparing polymyxin B Etest with broth microdilution and only 6.4% minor errors with colistin. The concordance between Etest and the broth microdilution (reference method) was respectively 100% for colistin and 90% for polymyxin B. Conclusion Resistance to polymyxins seems to be rare among hospital carbapenem-resistant P. aeruginosa isolates over a six-year period. Our results showed, using the new CLSI criteria, that the disc diffusion susceptibility does not report major errors (false-resistant results) for colistin. On the other hand, showed a high frequency of minor errors and 1 very major error for polymyxin B. Etest presented better results for colistin than polymyxin B. Until these results are reproduced with a large number of polymyxins-resistant P. aeruginosa isolates, susceptibility to polymyxins should be confirmed by a reference method.

Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland

We analyzed the species distribution of Candida blood isolates (CBIs), prospectively collected between 2004 and 2009 within FUNGINOS, and compared their antifungal susceptibility according to clinical breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in 2013, and the Clinical and Laboratory Standards Institute (CLSI) in 2008 (old CLSI breakpoints) and 2012 (new CLSI breakpoints). CBIs were tested for susceptiblity to fluconazole, voriconazole and caspofungin by microtitre broth dilution (Sensititre® YeastOne™ test panel). Of 1090 CBIs, 675 (61.9%) were C. albicans, 191 (17.5%) C. glabrata, 64 (5.9%) C. tropicalis, 59 (5.4%) C. parapsilosis, 33 (3%) C. dubliniensis, 22 (2%) C. krusei and 46 (4.2%) rare Candida species. Independently of the breakpoints applied, C. albicans was almost uniformly (>98%) susceptible to all three antifungal agents. In contrast, the proportions of fluconazole- and voriconazole-susceptible C. tropicalis and F-susceptible C. parapsilosis were lower according to EUCAST/new CLSI breakpoints than to the old CLSI breakpoints. For caspofungin, non-susceptibility occurred mainly in C. krusei (63.3%) and C. glabrata (9.4%). Nine isolates (five C. tropicalis, three C. albicans and one C. parapsilosis) were cross-resistant to azoles according to EUCAST breakpoints, compared with three isolates (two C. albicans and one C. tropicalis) according to new and two (2 C. albicans) according to old CLSI breakpoints. Four species (C. albicans, C. glabrata, C. tropicalis and C. parapsilosis) represented >90% of all CBIs. In vitro resistance to fluconazole, voriconazole and caspofungin was rare among C. albicans, but an increase of non-susceptibile isolates was observed among C. tropicalis/C. parapsilosis for the azoles and C. glabrata/C. krusei for caspofungin according to EUCAST and new CLSI breakpoints compared with old CLSI breakpoints.

In vitro activity of clinically implemented β-lactams against Aerococcus urinae: presence of non-susceptible isolates in Switzerland.

We analyzed the in vitro susceptibility to several ?-lactams and vancomycin of 80 Aerococcus urinae isolates col- lected during 2011-2012 in Switzerland. MICs were determined by Etest (bioMérieux) on Müller-Hinton agar with 5% sheep blood and interpreted according to the CLSI and EUCAST criteria set for viridans streptococci. MIC50/90 for penicillin, amoxicillin, ceftriaxone and vancomycin were 0.016/0.064 mg/l, 0.032/0.064 mg/l, 0.125/0.5 mg/l and 0.38/0.5 mg/l, respectively. Three (3.8%) isolates were resistant to ceftriaxone regardless of the criteria used (MICs ?2 mg/l); one of them was also non-susceptible to penicillin (MIC of 0.25 mg/l) according to CLSI. ?-lactam resis- tance in A. urinae is a concern and suggests that more studies are needed to determine the molecular mechanisms of such resistance.

The cystatin C/creatinine ratio, a marker of glomerular filtration quality: associated factors, reference intervals, and prediction of morbidity and mortality in healthy seniors.

The ratio of cystatin C (cysC) to creatinine (crea) is regarded as a marker of glomerular filtration quality associated with cardiovascular morbidities. We sought to determine reference intervals for serum cysC-crea ratio in seniors. Furthermore, we sought to determine whether other low-molecular weight molecules exhibit a similar behavior in individuals with altered glomerular filtration quality. Finally, we investigated associations with adverse outcomes. A total of 1382 subjectively healthy Swiss volunteers aged 60 years or older were enrolled in the study. Reference intervals were calculated according to Clinical & Laboratory Standards Institute (CLSI) guideline EP28-A3c. After a baseline exam, a 4-year follow-up survey recorded information about overall morbidity and mortality. The cysC-crea ratio (mean 0.0124 ± 0.0026 mg/μmol) was significantly higher in women and increased progressively with age. Other associated factors were hemoglobin A1c, mean arterial pressure, and C-reactive protein (P < 0.05 for all). Participants exhibiting shrunken pore syndrome had significantly higher ratios of 3.5-66.5 kDa molecules (brain natriuretic peptide, parathyroid hormone, β2-microglobulin, cystatin C, retinol-binding protein, thyroid-stimulating hormone, α1-acid glycoprotein, lipase, amylase, prealbumin, and albumin) and creatinine. There was no such difference in the ratios of very low-molecular weight molecules (urea, uric acid) to creatinine or in the ratios of molecules larger than 66.5 kDa (transferrin, haptoglobin) to creatinine. The cysC-crea ratio was significantly predictive of mortality and subjective overall morbidity at follow-up in logistic regression models adjusting for several factors. The cysC-crea ratio exhibits age- and sex-specific reference intervals in seniors. In conclusion, the cysC-crea ratio may indicate the relative retention of biologically active low-molecular weight compounds and can independently predict the risk for overall mortality and morbidity in the elderly.

Evaluación de moxifloxacino como tratamiento alternativo en las infecciones por "Stenotrophomonas maltophilia": optimización de dosis empleando sistemas farmacodinámicos

Stenotrophomonas maltophilia es un patógeno nosocomial, emergente, cuya incidencia en procesos severos esta aumentado de manera análoga al incremento de las poblaciones de pacientes con factores predisponentes. S. maltophilia es un microorganismo ubicuo y adaptado a múltiples ambientes, lo que explica la elevada diversidad genética y el resistoma característico de esta especie que le confiere resistencia a la mayoría de clases de antimicrobianos. Se sugiere que el paciente porta al microorganismo en el momento del ingreso y que la combinación entre la presión antibiótica, especialmente aminoglucósidos y carbapenemas, y el profundo y prolongado estado de inmunosupresión favorecen el desarrollo de la infección. El tratamiento de las infecciones severas, bacteriemias y neumonías, es empírico, y relacionado con una elevada mortalidad, 36-67%, que es atribuida a que la mayoría de pacientes recibe una terapia inapropiada. La carencia de antimicrobianos con suficiente actividad, la rápida aparición de resistencias en los pacientes bajo tratamiento y la ausencia de ensayos clínicos que discriminen tratamientos efectivos, condicionan el complicado manejo de los pacientes infectados por S. maltophilia . En la actualidad solo seis antimicrobianos, cotrimoxazol, ticarcilina-ácido clavulánico, de elección y ceftazidima, levofloxacino, minociclina y cloranfenicol, son considerados tratamientos apropiados para este microorganismo por el CLSI o el EUCAST. La probabilidad de supervivencia aumenta con la rápida administración de agentes sensibles in vitro , pero la mortalidad continúa siendo extraordinariamente alta, 14 y el 45%, lo que demuestra la urgente necesidad de alternativas terapéuticas y de la revaloración de los actuales puntos de corte microbiológicos empleados en el pronóstico de eficacia clínica para esta especie...

Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients through Northern Europe

Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This study compares the antimicrobial susceptibility of 153 P. aeruginosa isolates from the United Kingdom (UK) (n=58), Belgium (n=44), and Germany (n=51) collected from 120 patients during routine visits over the 2006-2012 period. MICs were measured by broth microdilution. Genes encoding extended spectrum β-lactamases (ESBL), metallo-β-lactamases and carbapenemases were detected by PCR. Pulsed Field Gel Electrophoresis and Multi-Locus Sequence Typing were performed on isolates resistant to ≥ 3 antibiotic classes among penicillins/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, polymyxins. Based on EUCAST/CLSI breakpoints, susceptibility was ≤ 30%/≤ 40% (penicillins, ceftazidime, amikacin, ciprofloxacin), 44-48%/48-63% (carbapenems), 72%/72% (tobramycin), and 92%/78% (colistin) independently of patient's age. Sixty percent of strains were multidrug resistant (MDR; European Centre for Disease prevention and Control criteria). Genes encoding ESBL (most prevalent BEL, PER, GES, VEB, CTX-M, TEM, SHV, and OXA), metallo β-lactamases (VIM, IMP, NDM), or carbapenemases (OXA-48, KPC) were not detected. The Liverpool Epidemic Strain (LES) was prevalent in UK isolates only (75% of MDR isolates). Four MDR ST958 isolates were found spread over the three countries. The other MDR clones were evidenced in ≤ 3 isolates and localized in a single country. A new sequence type (ST2254) was discovered in one MDR isolate in Germany. Clonal and non-clonal isolates with different susceptibility profiles were found in 21 patients. Thus, resistance and MDR are highly prevalent in routine isolates from 3 countries, with carbapenem (meropenem), tobramycin and colistin remaining the most active drugs.

Estudo da atividade biológica de líquidos iónicos baseados em bis-piridínios em bactérias Gram-positivas e Gram-negativas

As resistências aos antibióticos estão a tornar-se um problema de saúde pública, estando a preocupar as várias entidades mundiais. Assim sendo, a descoberta de novas alternativas para combater infeções microbianas é crítica. Os líquidos iónicos (LIs) surgem, neste contexto, como um recurso a ser utilizado na indústria farmacêutica, nomeadamente na síntese de novos antibióticos. LIs demonstram a capacidade de melhorar as características dos ingredientes farmacêuticos ativos (API). No entanto, esta não é apenas a relevância destes compostos: propriedades antimicrobianas também têm sido descritas. LIs combinados com APIs ou LI como um API estão a dar uma nova perspetiva aos antibióticos. Os bis-piridínios estão, agora, a ser alvo de estudos também nesta área. Propriedades antimicrobianas de bis-piridinio têm sido descritas. O objetivo deste estudo foi avaliar a atividade de sais bis-piridínios como antimicrobianos. Os LIs derivados de bis-piridínio foram sintetizados e purificados pelo grupo Luís C. Branco da Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, e usado após a confirmação das estruturas e pureza por ressonância magnética nuclear e espectrometria de massa. As bactérias utilizadas pertencem à coleção de Química e Biomoléculas da ESTSP. Para avaliar a atividade biológica dos compostos foram determinados os valores de concentração mínima inibitória (MIC), pelo método de microdiluição, de acordo com a metodologia do Clinical Laboratory Standards Institute (CLSI). A determinação das taxas de crescimento também foi feita pelo método de microdiluição. Foram estudados 12 LIs contra 9 estirpes bacterianas, muitas das quais resistentes aos antibióticos. Apenas três dos compostos não mostraram nenhuma atividade antimicrobiana para as concentrações estudadas (<5 mM). Dois LIs mostraram atividade biológica contra todas as bactérias estudadas, incluindo o S.aureaus MRSA ATCC 43300. Seis dos sete restantes compostos demonstraram atividade biológica contra a maioria das bactérias estudadas. Só um composto mostrou atividade contra uma única bactéria. Os LIs bis-piridínios têm atividade biológica contra bactérias Gram-positivas e Gram- negativas, incluindo bactérias resistentes. Assim, estes compostos devem ser tidos em conta na busca de novas moléculas antibacterianas (síntese de novos antibióticos ou desinfetantes).

Resistencia antimicrobiana de Staphylococcus aureus en pacientes con pie diabético que asisten a la consulta externa del Hospital Nacional Dr. Jorge Arturo Mena de Santiago de María, departamento de Usulután en el período de junio a agosto de 2014

La resistencia bacteriana es uno de los problemas de Salud Pública más graves, los microorganismos que causan enfermedades infecciosas han dejado de responder a los antibióticos de uso común; en la investigación el objetivo fue determinar la resistencia antimicrobiana de Staphylococcus aureus en pacientes con pie diabético que asistieron a la Consulta Externa del Hospital Nacional Dr. Jorge Arturo Mena de Santiago de María, departamento de Usulután en el período de junio a agosto de 2014; a los antibióticos Eritromicina, Clindamicina, Ampicilina, Ciprofloxacina, Ceftriaxona, Cotrimoxazol; utilizados en el tratamiento de infecciones por bacterias grampositivas, para lo cual se observaron y analizaron 30 muestras de personas con pie diabético para obtener una población de 10 personas a quienes se les aisló la bacteria Staphylococcus aureus y se les realizó el respectivo antibiograma. Metodología fue un estudio de tipo prospectivo, transversal, descriptivo y de campo; los datos obtenidos fueron ordenados y tabulados en donde se obtuvieron las siguientes Resultados se determinó que existe resistencia antimicrobiana de Staphylococcus aureus a los antibióticos: Eritromicina 70%, Clindamicina 60%, Ampicilina 60%, Ciprofloxacina 50%, Ceftriaxona 40% y Crotrimoxazol 20%; en pacientes con pie diabético que asistieron a la Consulta Externa del Hospital Nacional Dr. Jorge Arturo Mena de Santiago de María; mediante la utilizando la técnica de Kirby-Bauer y se cumplió con la norma del CLSI (Clinical and Laboratory Standards Institute). La población en estudio manifestó no conocer que el no tomar el tratamiento completo puede producir resistencia bacteriana 60%, el 90% recibió tratamiento con el antibiótico Ciprofloxacina, 70% Eritromicina, 50% Clindamicina y Ampicilina; el 60% no recordaba cuantas veces había recibido tratamiento con los antibióticos mencionados, factores que contribuyen a las complicaciones de quienes padecen pie diabético y son tratados por infecciones bacterianas.También se obtuvo resistencia antimicrobiana de otras bacterias aisladas en el estudio, donde: Enterococcus sp presentó una resistencia en un 100% a los antibióticos Cotrimoxazol, Ceftriaxona y Ciprofloxacina, al igual que Pseudomonas sp que es una bacteria nosocomial, manifestó ser resistente en un 50% a los 3 antibióticos; Escherichia coli presentó un 41.7% de resistencia al antibiótico Cotrimoxazol, Ciprofloxacina 33.3% y Ceftriaxona 25%; a diferencia de Proteus sp y Staphylococcus coagulasa negativa que no presentaron resistencia. Conclusiones: Staphylococcus aureus presento mayor resistencia al antibiótico Eritromicina 70%; uno de los factores que influye puede ser que la población en estudio manifestó en un 60% no saber que el abandonar los tratamientos producen resistencias bacteriana.

Green synthesis of silver nanoparticles using Arbutus andrachne leaf extract and its antimicrobial activity

Purpose: To synthesize silver nanoparticles (AgNPs) of Arbutus andrachne leaf water extract (LE) and to evaluate the antimicrobial activity of both LE and AgNPs. Methods: The synthesized AgNPs were characterized using the following techniques: ultraviolet-visible spectroscopy (UV-vis), Fourier transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), thermal gravimetric analysis (TGA), X-ray diffraction (XRD) analysis, and analysis of particle size (PS) and zeta potential (ZP). The antimicrobial activities of LE and NPs were assessed by Kirby-Bauer disc diffusion (DD) and broth microdilution (MD) methods according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI). LE and AgNPs were examined against fresh cultures of four Gram-positive and five Gram-negative bacteria, and three yeast strains. Results: AgNPs were successfully synthesized and characterized using Arbutus andrachne LE. The AgNPs showed moderate antibacterial activity against Staphylococcus aureus ATCC 6538p, S. epidermidis ATCC 12228, Escherichia coli ATCC 29998, Klebsiella pnemoniae ATCC 13883 and Pseudomonas aeruginosa ATCC 27853, and also antifungal activity against Candida albicans ATCC 10239 and C. krusei ATCC 6258. Conclusions: Due to the potent activity of AgNPs against Gram-positive and Gram-negative bacteria, and yeast strains, it is suggested that AgNPs are potential broad spectrum antimicrobial agents.

Perfil epidemiológico y análisis de la formulación antibiótica en pacientes con infección urinaria nosocomial en la Fundación Cardioinfantil en el año 2014

Introducción: La IVU es muy frecuenten en la (FCI - IC), Alrededor el 60% de los pacientes con diagnóstico de IVU nosocomial corresponden a gérmenes resistente, Desde el año 2010 el CLSI disminuyó los puntos de corte de sensibilidad en las enterobacteriaceae y removió la necesidad de tamizaje y confirmación de (BLEE), en el presente trabajo se pretende determinar el perfil epidemiológico de la formulación antibiótica en pacientes con IVU nosocomial. Diseño: Se realizó un estudio observacional analítico de corte transversal. Métodos: Se realizó un análisis univariado, bivariado y multivariado. El análisis bivariado y multivariado se realizó para determinar la medida de asociación teniendo en cuenta la formulación de Carbapenemico la variable dependiente, evaluándose mediante chi cuadrado. Resultados: Se revisaron 131 urocultivos, se incluyeron 116. Los aislamientos microbiológicos más frecuentemente encontrados fueron E. Coli y K. Pneumoniae, el 43.4% de los aislamientos, presentaron expresión de BLEE, 90% de los aislamientos fueron sensibles a Cefepime. La mayoría de los modelos obtenidos mostraron una fuerte asociación entre el reporte de BLEE en antibiograma con la formulación de carbapenémicos como terapia final OR 33,12 IC 95% (2,90 – 337,4). Conclusión: La epidemiologia de la IVU nosocomial en la FCI-IC no difiere de las referencias internacionales, no hay adherencia a las guías de manejo intrahospitalario y el reporte de la palabra BLEE en el antibiograma predice la formulación de antibiótico carbapenémico por el médico que lee el urocultivo